Together with the PD-L1 induction associated with EBV infection44, this suggests potential for PD-1 blockade immunotherapy also in a subset of ANKL patients in addition to recently reported sensitivity of NKTCL to PD-1 inhibition45. Here, CD274 is linked to aggressive NK-cell leukemia.